Sio Gene Therapies, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sio Gene Therapies, Inc.
2020 has kicked off with a major European biotech deal that will see the Italian conglomerate Angelini take over Switzerland's Arvelle which is on the verge of getting EU approval for an anti-epilepsy drug licensed from SK Bio that got the green light in the US two years ago.
Myovant's Orgovyx was just approved by the US FDA for prostate cancer and could be approved soon for two women's health indications.
The development and commercialization of cell and gene therapies during a pandemic, with regulators and payers demanding more data on effect duration and safety, has resulted in headwinds. Added to manufacturing and clinical trial recruitment issues, investors’ patience has been strained.
Biopharma executives discussed their strategies for treating chronic diseases during the Cell and Gene Meeting on the Mesa, including R&D and regulatory considerations.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Arvelle Therapeutics GmbH
- Axovant Sciences GmbH
- Axovant Sciences, Inc.
- Axovant Sciences Ltd.
- Roivant Neurosciences Ltd.
- Axovant Gene Therapies Ltd.